Announcing OPAL: A First-in-Class OLIG2 Inhibitor Multisite Phase 1 Glioblastoma Clinical Trial
COGNO and ABCARA are delighted to announce the launch of the OPAL study – a national, multi-site Phase 1 clinical
COGNO and ABCARA are delighted to announce the launch of the OPAL study – a national, multi-site Phase 1 clinical
Multi-Arm Glioblastoma Australasia (MAGMA): Multi-Arm Randomised Clinical Trial For People Affected By Glioblastoma The COGNO-led MAGMA trial is a multi-arm
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2) trial platform across Australia and Canada COGNO is